Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
6.80
-0.05 (-0.73%)
At close: Dec 5, 2025, 4:00 PM EST
6.80
0.00 (0.00%)
After-hours: Dec 5, 2025, 8:00 PM EST
Nasus Pharma Statistics
Total Valuation
Nasus Pharma has a market cap or net worth of $61.61 million. The enterprise value is $63.12 million.
| Market Cap | 61.61M |
| Enterprise Value | 63.12M |
Important Dates
The next estimated earnings date is Tuesday, December 16, 2025, before market open.
| Earnings Date | Dec 16, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nasus Pharma has 9.06 million shares outstanding. The number of shares has decreased by -0.43% in one year.
| Current Share Class | 9.06M |
| Shares Outstanding | 9.06M |
| Shares Change (YoY) | -0.43% |
| Shares Change (QoQ) | +4.01% |
| Owned by Insiders (%) | 43.73% |
| Owned by Institutions (%) | 0.04% |
| Float | 2.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.12
| Current Ratio | 0.12 |
| Quick Ratio | 0.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -37.17 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -116.06% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 33.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$766,000 |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 7.49 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 42.65 |
| Average Volume (20 Days) | 2,988 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.08M |
| Pretax Income | -1.55M |
| Net Income | -1.53M |
| EBITDA | n/a |
| EBIT | -1.08M |
| Earnings Per Share (EPS) | -$0.22 |
Balance Sheet
The company has $284,000 in cash and $1.80 million in debt, giving a net cash position of -$1.52 million or -$0.17 per share.
| Cash & Cash Equivalents | 284,000 |
| Total Debt | 1.80M |
| Net Cash | -1.52M |
| Net Cash Per Share | -$0.17 |
| Equity (Book Value) | -3.21M |
| Book Value Per Share | -0.44 |
| Working Capital | -3.47M |
Cash Flow
| Operating Cash Flow | -665,000 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nasus Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.43% |
| Shareholder Yield | 0.43% |
| Earnings Yield | -2.49% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Nasus Pharma is $22.00, which is 237.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.00 |
| Price Target Difference | 237.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |